Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Terminated 6Active not recruiting 5Completed 4Recruiting 3Unknown 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Gastrointestinal 2Head & Neck 1Gynecologic 1Genitourinary 1Dermatologic 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 31Melanoma 20Neoplasms 13Breast Neoplasms 11Pancreatic Neoplasms 9Lung Neoplasms 9Head and Neck Neoplasms 9Triple Negative Breast Neoplasms 8Stomach Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Ovarian Neoplasms 8Neoplasm Metastasis 8Colorectal Neoplasms 7Carcinoma, Renal Cell 7Carcinoma, Hepatocellular 6Prostatic Neoplasms 4Hodgkin Disease 4Glioblastoma 4Carcinoma, Transitional Cell 4Carcinoma 4Uterine Cervical Neoplasms 3Liver Neoplasms 3Kidney Neoplasms 3Esophageal Squamous Cell Carcinoma 3Esophageal Neoplasms 3Adenocarcinoma 3Small Cell Lung Carcinoma 2Parkinson Disease 4, Autosomal Dominant Lewy Body 2Neoplasms, Squamous Cell 2Mesothelioma 2

Interventions

pembrolizumab 2Hyperthermic Intraperitoneal Chemotherapy 2Gemcitabine 2Cisplatin 2niraparib 1dostarlimab 1defactinib 1Vitamin B 12 1TroVax 1Thiostrepton 1Sorafenib 1Pemetrexed 1Oxaliplatin 1Nivolumab 1Mitomycin 1MAC321 1Leucovorin 1Immunotherapy, Adoptive 1Imatinib Mesylate 1IPI-549 1Folic Acid 1Dexamethasone 1Cytoreduction Surgical Procedures 1Bortezomib 1Blood Specimen Collection 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Unknown × Mesothelioma × pembrolizumab × Clear all
NCT05311618 2024-04-01

Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors

NGM Biopharmaceuticals, Inc

Phase 1 Unknown
71 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Squamous Cell Carcinoma of Head and Neck, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Melanoma, Mesothelioma, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Cholangiocarcinoma

NCT02758587 2018-03-19

Study of FAK (Defactinib) and PD-1 (Pembrolizumab) Inhibition in Advanced Solid Malignancies (FAK-PD1)

NHS Greater Glasgow and Clyde

Phase 1/2 Unknown
59 enrolled
GastrointestinalOther solid neoplasmThoracic

Carcinoma, Non-Small-Cell Lung, Mesothelioma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡